Company Overview
VivoSim Labs, Inc. operates as a specialized pharmaceutical and biotechnology services company focused on the testing of drugs and drug candidates using three-dimensional (3D) human tissue models of the liver and intestine. This operational focus allows the firm to provide partners with critical liver and intestinal toxicology insights through its new approach methodologies (NAM) models, addressing a specific niche within the broader healthcare sector. As a biotechnology entity, the company functions within an industry characterized by high innovation requirements and significant regulatory scrutiny regarding drug safety and efficacy. The company's scale is defined by a market capitalization of $4.22M, annual revenue of $142,000, and a workforce of 14 employees. These figures indicate that VivoSim Labs, Inc. is a micro-cap entity with minimal operational footprint, suggesting it is in an early-stage development phase where revenue generation is currently limited but strategic partnerships in toxicology modeling are being cultivated.
Financial Health
The company reports revenue of $142,000 over the trailing twelve months, yet it simultaneously reports a net income of $-1,227,000 and an EBITDA of $-11,221,000. The substantial gap between the positive revenue and the significant negative net income and EBITDA reveals a cost structure dominated by heavy upfront expenses, likely related to research and development or operational scaling that outpaces current revenue generation. The firm generates free cash flow of $-7,895,875, which indicates a consumption of cash resources that limits immediate financial flexibility and necessitates reliance on existing cash reserves or external financing to sustain operations. Analysis of the margin profile shows a gross margin of 0.0%, an operating margin of -10576.9%, and a profit margin of 0.0%, all of which reflect the early-stage nature of the business where costs are incurred without corresponding gross profitability or operating leverage. In terms of balance sheet leverage, the company holds cash of $4.29M against debt of $812,000, resulting in a debt-to-equity ratio of 18.28, which suggests a capital structure heavily weighted toward equity financing rather than debt obligations. The current ratio stands at 2.44, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable buffer. Return on equity is -51.1% and return on assets is -132.5%, metrics that reveal that management effectiveness in generating positive returns from shareholder capital and total assets is currently negative due to the accumulation of losses relative to the company's equity and asset base.
Valuation Assessment
The trailing P/E ratio is 0.92 while the forward P/E is N/A, implying that the market is pricing the stock based on historical earnings that are barely positive or negligible, whereas future earnings expectations are not yet quantifiable by a standard multiple. The price-to-book ratio is 0.95, which indicates that the market is valuing the company at a slight discount to its net book value, rather than applying a premium for growth potential or intangible assets. Alternative valuation metrics further illustrate the company's unique position; the price-to-sales ratio is 29.75, while the EV/EBITDA is -0.07, suggesting that the stock is priced high relative to its minimal sales volume and that the negative EV/EBITDA reflects the company's current lack of earnings power. The stock trades with a 52-week high of $5.30 and a 52-week low of $1.41, meaning the current price sits somewhere within this range, subject to market sentiment and trading volume fluctuations. The beta value is 1.32, which signifies that the stock's price volatility is higher than the broader market, moving 32% more than the market index on average during periods of price swings.
Growth & Income
VivoSim Labs, Inc. reports revenue growth of 8.3% year-over-year, while earnings growth is N/A, indicating that the company is expanding its top line but has not yet achieved a stage where earnings growth can be meaningfully compared or where profitability is positive enough to drive that metric. Because the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which explains that the firm reinvests any available earnings or cash flow directly into operations and growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by revenue expansion in a specialized service sector, coupled with a complete absence of current profitability and dividend income.